Orchid Pharma Ltd

Orchid Pharma Earnings Call: Key Takeaways

Orchid Pharma reports FY26 standalone revenue of ₹811 Cr and PAT of ₹45 Cr, focusing on transitioning from a turnaround to an integrated cephalosporin platform with major capex in 7ACA.

Orchid Pharma Management Change

Orchid Pharma appointed M/s. T R Chadha & Co. LLP as its Internal Auditor for a 12-month term. The appointment strengthens the company's internal control and governance frameworks.

Execution

12 months

Orchid Pharma Q4 FY26 Results: Net Profit ₹23.8 Cr, Up 6.7% YoY

Orchid Pharma Ltd reported revenue from operations of ₹237.6 Cr (+0.0% YoY) and net profit of ₹23.8 Cr (+6.7% YoY) for Q4 FY26.

Key figure

Net profit ₹23.8 Cr · +6.7% YoY

Orchid Pharma Financial Results

Orchid Pharma approved audited FY2026 results and appointed T R Chadha & Co. LLP as internal auditors. The consolidated net profit for the year stood at ₹21.21 Crore.

Orchid Pharma Board Meeting Date

Orchid Pharma scheduled a board meeting for May 25, 2026, to approve fiscal 2026 audited financial results. The trading window remains closed until 48 hours post-declaration.

Orchid Pharma Fund Raise of ₹400 Cr

Orchid Pharma Limited submitted its Monitoring Agency Report for the Rs. 400 Crore QIP. The funds are being utilized as per revised shareholder-approved objects.

Value

₹400.0 Cr

Orchid Pharma Legal & Regulatory

The National Company Law Tribunal (NCLT), Chennai Bench, dismissed an application filed by DBS Bank against Orchid Pharma Limited. The claim involved lease rent dues during the Corporate Insolvency Resolution Process (CIRP) period. The tribunal's order, dated April 02, 2026, has no quantifiable financial impact on the company.